Washington — In a Senate Health Committee hearing on Thursday, President Donald Trump’s choice to lead the Food and Drug Administration, Dr. Heidi Overton, reaffirmed the safety of long‑standing vaccines. Overton, a physician and current White House adviser, emphasized that every vaccine on the market has been determined to be safe and effective, including the measles, mumps and rubella (MMR) vaccine.
Administration’s goal to modernize vaccine schedule
Overton has helped shape several Trump health initiatives, including an executive order that proposes splitting up and spacing out decades‑old childhood vaccinations. The administration argues that a more flexible schedule could better align with modern medical practice and parental choice, while still protecting public health.
Senate questioning and administration response
Senate Health Committee Chairman Sen. Bill Cassidy, a physician from Louisiana, pressed Overton to reject the president’s earlier comment that the combined MMR vaccine could be “quite lethal.” Overton responded firmly that the vaccine is safe, noting that the FDA’s rigorous review process ensures both safety and effectiveness.
When asked whether she would stand up for sound science and protect children’s health, Overton said she would “follow the statutory requirements” for FDA commissioners and give President Trump her best advice. She did not directly label the president’s earlier remark as incorrect, but she made clear her commitment to scientific standards.
Other pending FDA issues
If confirmed, Overton will inherit several high‑profile projects. One is a safety review of the nation’s principal abortion medication, mifepristone, a topic that has drawn bipartisan attention. Overton noted that the drug “has met the safety and efficacy determinations of the FDA,” and she pledged to ensure that any companies involved comply with the law.
Another focus is new rules that make it easier to sell flavored electronic cigarettes. Overton explained that FDA scientists have determined certain fruit‑flavored vaping products meet the standard of “appropriate for the protection of public health” because they help adult smokers quit cigarettes.
Political dynamics
The nomination will require a majority vote from the 21‑member health committee and a full Senate confirmation. Republican senators, including Sen. Jim Banks of Indiana, expressed support for Overton’s commitment to enforce the law. Moderate Republican senators such as Sen. Susan Collins of Maine and Sen. Lisa Murkowski of Alaska, who have historically supported federal access to abortion, may weigh the nominee’s stance on the mifepristone review.
Sen. Cassidy, a Republican, reiterated the committee’s need for “radical honesty” and a commissioner who will protect children’s health through science‑based decisions. He did not indicate when a final vote might occur.
Background on the nominee
Dr. Overton earned her medical degree from the University of New Mexico and a doctorate in clinical research from Johns Hopkins University, where she studied under former FDA head Dr. Marty Makary. Like her predecessor, Overton has limited experience running a large bureaucracy, a challenge she acknowledges as she prepares to oversee the agency’s 16,000 staff worldwide.
In financial disclosure forms, Overton reported no investments in healthcare or food companies, contrasting with some prior FDA nominees who had to divest holdings. She disclosed $50,000 to $100,000 in student loans.
Implications for families and faith communities
The administration’s focus on vaccine safety and parental choice aligns with traditional family values and the right of parents to make informed health decisions for their children. By emphasizing scientific rigor while pursuing schedule flexibility, the Trump administration seeks to balance public‑health protection with respect for family autonomy.
Original reporting: Texarkana Gazette — read the source article.
